Global access disparity (revision 3)
Old revision·08:15, 17 Jan 2025·TelehealthTruus
| Global access disparity | |
|---|---|
| Drivers | Price, manufacturing capacity, regulatory approval, coverage |
| Consequence | Availability tracks income between and within countries |
| Topic infobox · conventions | |
Global access disparity describes the uneven availability and affordability of incretin therapies. Availability tracks national income closely: approval, supply and coverage have concentrated in high-income markets, and the conditions these drugs treat are not so concentrated.[1]
Four factors drive it. Price, set within markets rather than globally. Manufacturing capacity, which for peptides is capital-intensive and was constrained during the demand growth of the 2020s. Regulatory approval, granted jurisdiction by jurisdiction. And coverage, which determines affordability where a product is available at all.[2]
Supply and manufacturing
[edit]Peptide manufacture at scale requires synthesis capacity, preparative chromatography capacity, and fill-finish capacity, each of which is capital-intensive and slow to build. Demand growth outpaced all three during the period these products expanded.[3]
Constrained supply is allocated by price and by contract, which concentrates it in markets able to pay. This is a market outcome rather than a policy decision, though policy shapes it.
References
- ^ World Health Organization, Obesity and Overweight fact sheet and associated global health estimates.
- ^ American Diabetes Association. "Standards of Care in Diabetes." Diabetes Care 47(Suppl 1) (2024).
- ^ United States Pharmacopeia, General Chapter <1503>, Quality Attributes of Synthetic Peptide Drug Substances.